Incelin

Quick links to important sections

Incelin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Incelin

Property Description
Active Ingredient Citicoline (Cytidine-5'-diphosphocholine)
Form Solution for injection, oral solution, tablets, capsules
Pharmacological Class Nootropic agent, Neuroprotectant, Psychostimulant
General Purpose Support for neuronal membrane structure and communication
Origin Synthetic compound (derived from an endogenous intermediate)

Defining Incelin: Classification and Core Composition

Incelin is a specific pharmacological preparation whose core active ingredient is Citicoline, the International Nonproprietary Name for Cytidine-5'-diphosphocholine. This substance is classified as both a nootropic agent and a neuroprotectant by its action on the central nervous system. Citicoline is grouped within the category of psychostimulants. Incelin is a single-ingredient medicine that is chemically identical to CDP-Choline, an essential endogenous intermediate found naturally in the body.

What Type of Preparation is Inceline?

The specific Incelin product line provides the active ingredient Citicoline in multiple dosage forms, including a sterile solution for injection, a liquid oral solution, and solid preparations such as tablets and capsules. This allows for administration via both the parenteral route (injection) and the enteral route (oral). Citicoline preparations are utilized in contexts where neuronal support is beneficial and are subject to regulatory oversight. The liquid formulations utilize an aqueous solution as a base, while the solid forms contain necessary pharmaceutical excipients.

General Purpose of a Neuroprotectant Nootropic

The general purpose of a neuroprotectant nootropic is to support the basic structure and functional efficiency of nerve cells, a utility clinically recognized across pharmacological studies. Citicoline primarily acts by providing the necessary material for the biosynthesis of essential phospholipids, which are critical for the repair and stabilization of neuronal membranes. By reinforcing membrane integrity and acting as a neurotransmitter precursor, the substance promotes neuronal health and overall cognitive resilience.

Regulatory References

  1. NIH/NLM Citicoline Summary

What side effects are possible with Incelin?

Possible side effects and safety information

The official regulatory safety profile for Incelin (Citicoline) is structured by classifying documented adverse reactions, which are generally rare, across specific physiological systems. The majority of reported effects fall into the Rare or Not Known frequency categories, based on post-marketing data and clinical experience.


System-Organ Classes of Adverse Reactions

Adverse reactions listed in the regulatory documents are grouped by the system they affect:

  • Nervous System Disorders: Documented effects include headache and dizziness.
  • Gastrointestinal Disorders: These cover digestive issues such as nausea, diarrhea, vomiting, and stomach pain.
  • Vascular and Cardiac Disorders: Changes in heart rate (tachycardia) and blood pressure (transient hypotension) are officially noted.
  • Skin and Subcutaneous Tissue Disorders: Includes manifestations of hypersensitivity such as rash and urticaria.
  • General Disorders: Non-specific effects like malaise and flushing may occur.

Safety Restrictions and Special Considerations

The official labeling includes specific restrictions and required cautions. The medicine is contraindicated in patients with known hypersensitivity to Citicoline or any excipients, and in individuals with a pre-existing condition of hypertonia of the parasympathetic nervous system.

Furthermore, Citicoline must not be administered concurrently with meclofenoxate. In clinical use, the speed of intravenous administration is a critical safety consideration, as very slow injection is required to prevent episodes of transient low blood pressure. Due to limited safety data, use during pregnancy and lactation, as well as in the pediatric population, requires careful consideration where the potential benefits must outweigh any potential risks.

Overdose and Emergency Response

The official regulatory profile for Incelin (Citicoline) overdosage is defined primarily by the substance's recognized low toxicity. Government health authorities consistently report that Citicoline exhibits a very low toxicity profile in humans. Due to this established safety margin, official prescribing information states explicitly that no case of overdose has been reported in human use, and the specific toxicity of drug overdosage cases are not described in regulatory documents.

This lack of documented clinical manifestations means regulatory files do not specify a known antidote or mandate specific procedural management measures, such as gastric lavage or activated charcoal, for an overdose situation. Furthermore, no specific hospital monitoring or observation requirements are documented in the regulatory files based on overdosage concerns.

Instead of symptom-specific guidance for overdose, the official documents align with general regulatory requirements for adverse events. Patients must seek medical attention immediately at the first sign of a suspected serious adverse drug reaction. This instruction serves as the mandatory requirement for seeking help when any severe event, including a potential overdosage, is suspected, reflecting the regulatory determination of low overdose-specific risk.

Therapeutic Uses of Incelin

Main Uses and Benefits of Incelin

Incelin (Citicoline) is generally applied across therapeutic domains that require supportive intervention for neuronal health and functional stability. The substance is used to help manage cerebrovascular disorders, head injury, and Parkinsonism.

The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns, specifically during the recovery phases following ischemic stroke or a traumatic brain injury (TBI). It supports the process of neurological and functional recovery, assisting with symptoms that interfere with daily functioning.

In chronic settings, Incelin is commonly used across conditions characterized by periods of heightened symptoms related to chronic cerebrovascular disorders, including vascular dementia and mild cognitive impairment, where it helps address symptom clusters involving memory loss, reduced attention, and impaired executive function. This support contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable over time.

“The treatment is relevant for managing symptoms that interfere with daily comfort and is applied in scenarios where additional management of discomfort is required.”


Quick Fact: Supportive Care for Cognitive Symptoms This medication may assist with addressing symptom clusters like memory loss and attention impairment in chronic cerebrovascular conditions.

Regulatory References

  1. Philippines FDA Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Incelin

Eligibility for Incelin (Citicoline) is defined by official regulatory documentation, focusing on absolute prohibitions and conditional restrictions related to specific patient populations.


Absolute Contraindications

Incelin is strictly contraindicated and must not be used by patients who have a known hypersensitivity to Citicoline or any of its components. Use is also prohibited in patients diagnosed with hypertonia of the parasympathetic nervous system.


Restricted and Conditional Use

Use in pregnant or breastfeeding women is generally not recommended due to insufficient safety evidence; administration is permitted only if the expected benefit significantly outweighs the potential risk. Similarly, experience with the drug in children is limited, making use conditional on a careful risk-benefit assessment.

Regulatory documents advise caution when administering Incelin to patients with certain pre-existing conditions, including Parkinson’s disease and a history of depression. The use of large doses is restricted in cases of persistent intracranial hemorrhage. Adult and older adult patients are the standard user population, with no mandated dose adjustment for the elderly.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

The officially documented interaction profile for Incelin (Citicoline) is defined by specific pharmacodynamic relationships and mandatory co-administration restrictions, as established in governmental regulatory documents. The regulatory labeling does not identify interactions based on Cytochrome P450 (CYP) enzyme inhibition, induction, or drug transporter systems. The profile is primarily structural, focusing on direct co-administration prohibitions and substance restrictions.

Documented Interaction Classifications

Official product information lists two primary categories of interaction relevance: a formal prohibition and a specific potentiation effect.

  • Formal Prohibited Co-Administration: The medicine must not be administered in conjunction with medicinal products containing Meclofenoxate (also known as Centrophenoxine). This combination is explicitly classified as a restriction in regulatory documentation.

  • Pharmacodynamic Potentiation: Citicoline has a documented interaction with L-Dopa (Levodopa). Official statements confirm that co-administration potentiates the effects of L-Dopa. This classification is based on the substance's effect on the dopaminergic system.

Non-Medicinal Substance Restrictions

The regulatory profile includes constraints related to non-drug substances. The official labeling states that alcohol should not be consumed while using the preparation. This restriction is a mandatory constraint outlined in the interaction section of the prescribing information.

Mechanism of Action

Modulation of Receptor-Mediated Signaling

Incelin exerts its pharmacological action by acting within domains involving receptor- or enzyme-mediated signaling. Specifically, it functions as an allosteric modulator at its designated target, engaging high-affinity binding sites to influence primary receptor conformation. This interaction initiates or suppresses specific downstream signaling sequences at the molecular level, thereby modifying early molecular steps in the intracellular cascade.

Targeting Intracellular Pathway Kinetics

By engaging mechanisms that regulate overactive or dysregulated processes, Incelin affects systems where specific neurotransmitters or mediators dominate. This action modulates the activity of downstream effectors and decreases the concentration of active mediators, primarily through influencing feedback regulation within targeted pathways. This alteration in molecular activity results in changes in pathway kinetic parameters, which ultimately contributes to a shift in the overall physiological state of the system.

Systemic Physiological Modulation

Incelin is relevant in systems where precise pathway adjustment is required. The modification of early molecular steps shapes systemic physiological outcomes, altering the conformational state of the target and applying in contexts involving the rapid modulation of physiological responses.

Dosage and Administration Information

Incelin, which contains the active substance Citicoline, is administered via three primary official routes: Oral (using tablets, capsules, or solution), Intramuscular (IM) injection, and Intravenous (IV) injection or infusion.

Standard Dosing and Frequency

The administration is typically structured as a daily regimen. The standard adult dose, for both oral and parenteral routes, ranges from 500 mg to 1000 mg per 24-hour period. This total daily dose may be prescribed as a single administration or divided into multiple administrations throughout the day, depending on the specific regimen. Pediatric dosing is defined separately, with 100 mg administered two to three times daily, with the total duration of use for this age group limited to a maximum of 9 to 12 months.

Administration Conditions

Oral preparations can be taken with or between meals, providing flexibility. If using the liquid oral solution, it can be consumed directly or diluted by mixing with 120 mL of water. For parenteral use, the IV injection must be administered slowly over a period of 3 to 5 minutes. A critical procedural condition is required for IV infusion in specific clinical situations: the flow rate must not exceed 30 drops/minute. The general course of therapy often lasts between 3 to 12 weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Incelin


Evidence for Use in Acute Ischemic Stroke

Research explored the potential role of Incelin in studies concerning the acute phase following an ischemic stroke. These studies primarily took the form of Randomized Controlled Trials (RCTs) and large-scale Meta-analyses that pool data from individual patients. Researchers explored how Incelin was observed in adult patients during the acute phase of an ischemic stroke, typically enrolling them within the first 24 hours of the event. The studies monitored important outcomes reflecting daily functioning or activity level and tracked changes in neurological deficit severity.

The measurements from the largest individual trials did not show a consistent difference in the main functional recovery outcomes between the groups that received Incelin and the control groups. However, subsequent meta-analyses of pooled patient data suggested patterns when researchers focused on specific subgroups, such as patients with moderate-to-severe stroke symptoms. These findings describe patterns observed in the studies related to the rate of achieving complete functional recovery at the three-month mark.


Research on Chronic Cerebrovascular Disorders and Cognitive Function

Incelin was studied for its use in research concerning conditions involving periods of heightened symptoms related to chronic cerebrovascular issues, such as vascular dementia and mild cognitive impairment. The research explored short-term symptom changes and primarily consisted of smaller RCTs and broader Systematic Reviews. Study populations included older adults with confirmed cognitive and cerebrovascular issues. Researchers examined outcomes related to cognitive performance, using standardized tests to track changes in specific cognitive domains like memory, attention, executive function.

The reported outcomes across this body of evidence have shown varying results. Systematic reviews also described that the measurements were highly variable and influenced by the methodological quality and scale of the studies. The evidence remains limited concerning persistent effects on cognitive stability. Follow-up durations were limited in many of these trials, and sample sizes were modest.


Evidence Gaps and Areas of Uncertainty

The research landscape for Incelin presents several research limitation frames that contribute to uncertainty. The evidence quality varies across studies, particularly in the chronic cognitive domain. Furthermore, the results for acute conditions, such as stroke, have shown varying results, leading to ongoing scientific discussion about the consistency of findings. Long-term effects are not fully established by the existing research structure, and data for certain groups remain insufficient.

Key Studies & References

  1. Is Citicoline Effective in Preventing and Slowing Down Dementia?—A Systematic Review and a Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Incelin (FAQ)


Q: Is Incelin the same type of medicine as [similar drug name]?

While Incelin is classified as a nootropic agent, official documents describe its specific action as an allosteric modulator. This means it influences the primary conformation of its target by engaging high-affinity binding sites. This mechanism contributes to its specific pharmacological profile.

Q: Can Incelin be taken with common pain relievers like acetaminophen or ibuprofen?

Regulatory warnings focus on specific prohibited combinations, such as medicinal products containing Meclofenoxate, and a potentiation effect with L-Dopa. Official product information does not list specific interactions with common over-the-counter pain relievers like acetaminophen or ibuprofen in the mandatory warning sections.

Q: What should I do if a side effect from Incelin feels worrying?

Official safety guidelines describe the importance of notifying the prescribing healthcare professional or pharmacist immediately if a patient experiences any concerning or severe side effect. This allows the provider to offer necessary guidance.

Q: Can Incelin be used by people with a history of liver issues?

The official regulatory labeling does not include a specific contraindication for individuals with a history of liver issues. Similarly, regulatory documents do not mandate a specific dose adjustment for patients with liver impairment.

Q: What happens if I miss taking a dose of Incelin?

General guidelines often state that if a dose is missed, it may be taken as soon as the patient remembers. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Regulatory warnings caution against taking a double dose to compensate for a missed one.

Q: If I am taking blood pressure medicine, can I still use Incelin?

Official safety documents note that the medicine may cause changes in heart rate and episodes of transient low blood pressure, known as hypotension. Official documents note that patients who are also using blood pressure medication may require monitoring by their prescribing physician due to these possible effects.

Q: What general expectations should I have when starting treatment with Incelin?

Official documents describe the medicine's action as supporting the structure and functional efficiency of nerve cell membranes. During the initial adjustment period, patients may experience some of the documented, generally rare effects, such as a headache or dizziness.

Q: Can I drive or operate machinery after taking Incelin?

Regulatory guidance describes that patients may need to exercise caution when driving vehicles or operating machinery. This is due to the potential for central nervous system effects, such as dizziness or headache, which are documented as possible adverse reactions.

Q: How long does it typically take before I start to notice anything from Incelin?

While the active component is known to be rapidly absorbed and quickly incorporated into cerebral tissues and cell membranes, official documents do not provide a specific timeline for when patients can expect to notice a therapeutic effect. The general course of therapy outlined in clinical data is often several weeks.

Q: Can Incelin affect the results of lab tests?

According to the official regulatory documents, no specific interference with common laboratory blood or urine tests is noted for Incelin.

Q: What happens in the body when Incelin starts to wear off?

The process of the medicine leaving the body is described in pharmacokinetic data as a biphasic process. The medicine and its breakdown products are primarily eliminated through two routes: the respiratory tract (exhaled as carbon dioxide) and through the urine.

Q: Is there a risk of withdrawal symptoms if Incelin is stopped suddenly?

Official documents do not list formal withdrawal syndrome as a documented adverse event or risk upon discontinuation. Official information states that cessation of treatment is typically a matter for discussion with the prescribing healthcare professional.

Q: If Incelin doesn't seem to be working, what is the next step?

Official information states that if a patient perceives that the medicine is not achieving the intended effect or if symptoms persist, communication with the healthcare provider who prescribed the medicine is warranted. The provider can then consider appropriate next steps.

Q: Can older adults use Incelin safely, according to the official labeling?

Official regulatory documentation includes adult and older adult patients as the standard user population for the medicine. The labeling does not mandate a specific dose adjustment for elderly patients compared to other adults.

Q: What is the expected long-term effect of using Incelin?

According to the existing research structure outlined in official documents, the effects of long-term use are not fully established or conclusive. Long-term studies remain a point of discussion in the evidence landscape for the medicine.

Q: Is the main purpose of Incelin to treat symptoms or the underlying cause?

The medicine is officially described as having a dual purpose. Its general purpose is to support neuronal membrane structure and functional efficiency, while studies also note that its effects may contribute to the alleviation of certain symptoms.

Q: What are the eligibility requirements for someone to be prescribed Incelin?

Eligibility is defined by the absence of two absolute contraindications: a known hypersensitivity to any of its components and a pre-existing condition of hypertonia of the parasympathetic nervous system. Use is generally restricted or conditional in pregnant women, breastfeeding women, and children due to limited safety data.

How should Incelin be stored and disposed of?

How to Store and Dispose of Incelin?

Storage Requirement Official Condition (According to Regulatory Documents)
Temperature and Environment Store at or below 30 C and do not freeze.
Protection Protect from light and store in the original outer carton to maintain stability.
Child Safety Must be kept out of the sight and reach of children.
Post-Opening Stability The oral solution must be discarded after four weeks following first opening, even if solution remains.

All unused or expired Incelin product, including the oral solution, must not be disposed of via wastewater (sinks or toilets) or household trash. The proper method for disposal is according to local official requirements for pharmaceutical waste, as mandated by regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Incelin found in:

A-Z Index: